肿瘤临床药师参与免疫检查点抑制剂全流程药学服务实践OA
Practice of Oncology Clinical Pharmacists' Participating in the Full-Process Pharmaceutical Care for Immune Checkpoint Inhibitors
目的 为使用免疫检查点抑制剂(ICIs)治疗的肿瘤患者提供更精准、安全的药学服务.方法 选取医院 2023 年 1 月 1 日至2024 年 6 月 30 日使用ICIs治疗的肿瘤患者 170 例,按随机数字表法分为对照组和观察组,各 85 例.两组均给予包括评估遴选、药学监护、质量控制管理的ICIs使用的全流程药学服务,其中仅观察组有肿瘤临床药师参与,对比分析两组免疫相关不良事件(irAEs)发生率、临床疗效、住院相关费用、医护及患者满意情况.结果 对照组与观察组irAEs总发生率(40.00%比 34.11%)及客观缓解率(18.82%比 28.24%)均相当(P>0.05),且观察组疾病控制率显著高于对照组(87.06%比 72.94%,P<0.05);两组患者住院总费用、药品总费用、ICIs费用均无显著差异(P>0.05).观察组患者满意度评分显著高于对照组[(8.80±0.69)分比(8.21±0.34)分,P<0.05].结论 肿瘤临床药师参与ICIs全流程药学服务,有利于逐步规范ICIs使用,确保患者得到安全、有效、经济的治疗效.
Objective To provide more precise and safe pharmaceutical services for tumor patients treated with immune checkpoint inhibitors(ICIs).Methods A total of 170 patients treated with ICIs from January 1,2023 to June 30,2024 in the hospital were selected and randomly divided into the control group and the observation group,with 85 cases in each group.Both groups were given full-process pharmaceutical care for the use of ICIs,including assessment and selection,pharmaceutical care,and quality control management.However,only the observation group had the participation of oncology clinical pharmacists.The incidence of immune-related adverse events(irAEs),clinical efficacy,hospitalization-related costs,and satisfaction of medical staff and patients were compared between the two groups.Results The overall incidence of irAEs and the objective response rate between the control group and the observation group were comparable(40.00%vs.34.11%,18.82%vs.28.24%,P>0.05),while,the disease control rate in the observation group was significantly higher than that in the control group(87.06%vs.72.94%,P<0.05).There were no significant differences in total hospitalization costs,total drug costs,and ICIs costs between the two groups(P>0.05).The patients'satisfaction score in the observation group was significantly higher than that in the control group[(8.80±0.69)points vs.(8.21±0.34)points,P<0.05].Conclusion The participating of oncology clinical pharmacists in the full-process pharmaceutical care for ICIs is conducive to gradually standardizing the use of ICIs and ensuring that patients receive safe,effective,and economical therapeutic effects.
任文艳;唐春梅;蒋心瑞;胡晓燕;唐志勇;杨思芸
首都医科大学附属北京安贞医院南充医院·南充市中心医院,四川 南充 637000||川北医学院第二临床医学院,四川 南充 637000||个体化药物治疗四川省南充市重点实验室,四川 南充 637000首都医科大学附属北京安贞医院南充医院·南充市中心医院,四川 南充 637000||川北医学院第二临床医学院,四川 南充 637000||个体化药物治疗四川省南充市重点实验室,四川 南充 637000首都医科大学附属北京安贞医院南充医院·南充市中心医院,四川 南充 637000||川北医学院第二临床医学院,四川 南充 637000||个体化药物治疗四川省南充市重点实验室,四川 南充 637000首都医科大学附属北京安贞医院南充医院·南充市中心医院,四川 南充 637000||川北医学院第二临床医学院,四川 南充 637000||个体化药物治疗四川省南充市重点实验室,四川 南充 637000首都医科大学附属北京安贞医院南充医院·南充市中心医院,四川 南充 637000||川北医学院第二临床医学院,四川 南充 637000||个体化药物治疗四川省南充市重点实验室,四川 南充 637000首都医科大学附属北京安贞医院南充医院·南充市中心医院,四川 南充 637000||川北医学院第二临床医学院,四川 南充 637000||个体化药物治疗四川省南充市重点实验室,四川 南充 637000
医药卫生
免疫检查点抑制剂肿瘤临床药师全流程药学服务
immune checkpoint inhibitoroncology clinical pharmacistfull-process pharmaceutical care
《中国药业》 2026 (6)
34-37,4
四川省南充市科技项目(市校科技战略合作专项)[22SXQT0358,22SXQT0015].
评论